We showed previously that the induction of neural crest (NC) and neural tube (NT) defects is a general property of N-methyl-D-aspartate receptor (NMDAR) antagonists. Since homocysteine induces NC and NT defects and can also act as an NMDAR antagonist, we hypothesized that the mechanism of homocysteine-induced developmental defects is mediated by competitive inhibition of the NMDAR by homocysteine. If this hypothesis is correct, homocysteine-induced defects will be reduced by NMDAR agonists. To test the hypothesis, we treated chicken embryos during the process of neural tube closure with sufficient homocysteine thiolactone to induce NC and NT defects in ϳ40% of survivors or with homocysteine thiolactone in combination with each of a selected set of NMDAR agonists in 0.05-5000 nmol doses. Glutamate site agonists selected were L-glutamate and N-methyl-D-aspartate. Glycine site agonists were glycine, D-cycloserine, and aminocyclopropane-carboxylic acid. Glycine was the most effective overall, reducing defects significantly at two different doses (each P>0.001). These results support the hypothesis that homocysteine may affect NC and NT development by its ability to inhibit the NMDAR. One potentially important consequence of this putative mechanism is that homocysteine may interact synergistically with other NMDAR antagonists to enhance its effect on development. 
A substantial body of experimental and epidemiologic evidence shows that folic acid deficiency is associated with the occurrence of congenital defects and that the periconceptional use of supplementary folate has a significant effect in protecting against the occurrence of certain defects (1) (2) (3) (4) (5) . This evidence reveals an especially well-documented association between periconceptional vitamin supplementation and a significant reduction in the rate of occurrence of neural tube and neural crest defects including failure of neural tube closure, conotruncal septation anomalies in the heart, and orofacial defects. Folic acid supplementation may provide protection against the occurrence of some other defects as well, but the association is not as well demonstrated. The cellular mechanism whereby folic acid confers this protection is not obvious; however, in the absence of sufficient folate, the amino acid homocysteine inevitably accumulates. It was hypothesized on the basis of epidemiologic studies that homocysteine per se may be a teratogenic agent in folic acid deficiency; indeed, hyperhomocysteinemia is associated with the same set of defects even when it is not caused by folic acid insufficiency (6 -8) . Our recent experimental findings using the avian embryo model supported this hypothesis: homocysteine induced neural tube, conotruncal, and orofacial defects in a time-and concentration-dependent fashion; and folic acid supplementation was effective in preventing these defects only when such supplementation resulted in a reduction of homocysteine (9) . This experiment did not show the cellular or molecular basis of the teratogenic effect of homocysteine.
In some experiments with adult cells, high concentrations of homocysteine may be cytotoxic; by extrapolation, it may be predicted that hyperhomocysteinemia might affect development adversely by killing embryonic cells. However, our initial experiments with hyperhomocysteinemia in the avian embryo model did not show evidence of necrosis in association with the occurrence of neural tube closure defects. The opposite was true: it was common to find duplication of the notochord, each copy of which was of normal size or larger; in most cases of abnormal neural tube closure, the spinal cord or brain appeared to have a superabundance of cells that were organized abnormally (9) . We concluded, therefore, that the induction of neural tube and related defects by homocysteine was not the result of its killing cells, but that a more subtle mechanism must be responsible.
Recently it was demonstrated that homocysteine has the ability to act as an antagonist of the N-methyl-D-aspartate (NMDA) 2 type of glutamate receptor (10 -12) . Although no previously published data specify a role for the activated NMDA receptor in neural tube closure or neural crest migration, there is evidence from later stages of development that the NMDA receptor is a principal regulator of neuronal cell migration, cell-to-cell adhesion, intracellular calcium flux, and programmed cell death (13) (14) (15) (16) (17) (18) , processes central to normal neural tube closure and neural crest migration. The NMDA receptor also behaves uniquely as a growth factor during neuronal development (19) . Furthermore, epidemiologic and experimental studies had shown that other NMDA receptor antagonists such as ethanol or certain anticonvulsants are associated with congenital defects of neural crest and neural tube derivatives (20 -25) . Therefore, we developed the hypothesis that homocysteine, acting as an NMDA receptor antagonist, could disrupt the orderly process of neural tube closure and neural crest migration by reducing the activity of an NMDA receptor (26) .
We reasoned that the initial series of experiments should test this new hypothesis physiologically: if activation of an NMDA receptor is important to normal neural tube closure or neural crest migration, then inhibition of NMDA receptor activity with selective antagonists will result in abnormal development of neural crest derivatives and the neural tube. When a set of compounds selected for their wellknown ability to act as highly specific antagonists of the NMDA receptor (e.g., MK801) were given to early chicken embryos, the results showed that the ability to disrupt neural crest/neural tube development was a general property of NMDA receptor antagonists (26) . If the mechanism of homocysteine teratogenicity involves its ability to inhibit the activity of the NMDA receptor, then the occurrence of homocysteine-induced defects will be reduced by activation of the NMDA receptor. The results described below show that the NMDA receptor coagonist glycine provided a highly significant level protection against homocysteine-induced developmental abnormalities.
MATERIALS AND METHODS

Embryo treatment protocol
The objective of this study was to test the hypothesis that activation of the NMDA receptor would protect early avian embryos from dysmorphogenesis induced by homocysteine. For these experiments, pathogen-free chicken embryos (SPAFAS, Preston, Conn.) were prepared for treatment and then given experimental solutions according to our protocol published previously (9, 26) . In summary, embryos in sets of 18 -20 were given one of the following solutions (50 l) at three time points during early development: 0.9% saline vehicle; 5 mol L-homocysteine thiolactone; or homocysteine thiolactone in combination with one of a selected set of NMDA receptor agonists (see below, Selected Agonists). We have shown previously that L-homocysteine thiolactone has the same teratogenic effect as L-homocysteine per se in keeping with its receptor-mediated (rather than metabolic) mode of action (26) , but the thiolactone form is significantly more stable in solution (9) . We have also shown that a dose of 5 mol of L-homocysteine thiolactone gives a good ratio of surviving embryos to embryos with defects (9, 26) . With this dose, serum homocysteine rose from 10 up to 140 nmol/ml within 2 h and then fell rapidly in stage 35 embryos; when supplementary folate kept the rise to Յ 40 nmol/ml, abnormal development was prevented (9) . Thus, a transitory peak of 40 -140 nmol/ml is sufficient to disrupt development in our model system. Concentrations in this range are achieved fairly frequently in humans after a high methionine meal (27) .
The time points selected for treatment were the prestreak stage (4 h of incubation), the 3-somite stage (28 h), and the 19 somite stage (48 -52 h). Solutions were delivered through a small access port just large enough to admit the tip of a 50 l pipette. This small opening was not associated with the occurrence of the 'windowing effect' described by the Schoenwolf laboratory (28) , who showed that a larger opening in the shell induced spinal closure defects by some mechanical influence; in this study and in previous reports by us, neural tube defects were rare among embryos that were windowed and then treated with vehicle control (Ͻ0.1%) (9, 26) . After delivery of each bolus of experimental drug, the small access port was covered with paraffin.
For each agonist (see below, Selected Agonists), the following were tested in a preliminary set of experiments: saline vehicle alone; 5 mol homocysteine thiolactone; 0.05, 0.5, 5.0, 50, 500, or 5000 nmol of the agonist; each of the above doses of agonist with 5 mol homocysteine thiolactone. Each of these experiments was repeated 3-9 times, using 18 -20 embryos for each repetition; thus, each solution was given to 60 -180 embryos. The treatment schedule described above was designed to expose the embryos to homocysteine during the processes of neurulation and gastrulation. All embryos were harvested upon the completion of neurulation, stage 20 -21, or 76 h of incubation to maximize survival. Treatment groups were coded so that the evaluation of developmental abnormalities could be performed blindly.
Evaluation of developmental abnormalities
Stage 20 -21 embryos were stained with the vital dye neutral red and inspected in a dissecting microscope; all gross developmental abnormalities were recorded. The abnormalities that were observed fell into the following categories: severe torsion (Ն270 o ) of the spinal cord without a neural tube closure defect; orofacial defects including small ( Fig. 1) or absent eye and absent or abnormal branchial arches (Fig.  1) ; spinal cord defects including closure defects in the thoracolumbar region [i.e., spina bifida (9)] or caudal regression; cranial closure defect, typically exencephaly (Fig. 2) ; or 'multiple defects', when a given embryo showed an obvious defect in two or more of the previous categories (Figs. 1, 2) . In a minority of the embryos that were treated with homocysteine thiolactone, there were blood-filled cysts among the caudal-most somites. These cysts were not statistically associated with any of the neural crest/neural tube abnormalities listed above, and it was not clear that their presence signaled any true developmental abnormality. A) The right side of the head and proximal thorax of a normal, vehicle-treated 76 h chicken embryo. Bain landmarks that were clearly differentiated included the telencephalon (tel), mesencephalon (mel), and metencephalon (met). The epiphysis (larger arrowhead, right) protruded above the diencephalon. The lens of the eye above the choroid fissure (smaller arrowhead, left) is well separated from the optic cup that surrounds it. The mandibular (1) and hyoid (2) arches of a size and shape typical for the stage. B) Left side of an embryo from the 'multiple defects' category that was treated with 5 mol L-homocysteine thiolactone/day for 3 days. There are no brain landmarks because of a closure defect that resulted in exencephaly (see Fig.  2 ). The mandibular (1) and hyoid (2) arches were thin-walled; the enclosed aortic arches were swollen, presumably the result of a lack of surrounding ectomesenchyme, giving the arches the balloon-like appearance shown. The choroid fissure of the left eye (arrowhead) was present, but the lens vesicle apparently had failed to separate and the lens was absent. The optic cup that surrounded the choroid fissure was greatly reduced in size compared with normal (see panel A above). This eye configuration was observed in several cases and was not taken as evidence of delayed normal eye development, since it did not recapitulate or even approximate the appearance of any stage of normal eye development. Figure 2A shows this embryo from the front, at the angle shown at 'a'; Fig. 2B shows it from the angle shown at 'b'. The nasal placode was large and displaced rostrally (arrow).
Figure 2.
A) The face of the embryo featured in Fig. 1 , from a shallow angle. Closure of the cranial portion of the neural tube failed completely and the nascent calvarium was absent, revealing the exencephalic brain. The nasal region was grossly asymmetrical (dashed midline); the naso-medial process was present on the left (nm) but not the right, as in some types of facial clefting. B) Face of the same embryo from a steeper angle. At this angle, it is clear that the epithelium (nascent epidermis) covering the frontal process formed a continuum with the region of the brain that would have been the lamina terminalis (asterisk). The exencephalic brain was divided into four sections by deep clefts, which formed a funnel into the central canal of the neural tube (right arrow). Obviously it was not possible to identify with certainty the regions of the brain in this and other embryos with cranial closure defects. However, a well-defined out-pouching of the brain in this embryo (left arrow) may be evidence for the location of the diencephalon, since the diencephalon is the only site where such out-pouchings normally occur, including the infundibulum, the epiphysis, and the recessus opticus. (The dotted letters 'HCYS' and the numbers '98 9 16' on these photographs are part of an intralaboratory recording code that prints automatically onto all negatives.) Selected embryos were fixed in Carnoy's fluid prepared with methanol, in which they may be stored indefinitely. To prepare them for photography, embryos were placed in normal saline at room temperature for 24 h, then the whole embryo was stained in toluidine blue for 3-5 min, rinsed in three changes of normal saline, and stored in 100% glycerol for 24 h. They were photographed in fresh glycerol. This method makes the embryos semitransparent and permits simultaneous visualization of surface and internal structures ( Figs. 1 and 2) , depending on the angle of the incident light.
Selected agonists
Two types of NMDA receptor agonist were selected. One set had the capacity to activate the receptor at the glutamate binding site and a second had the capacity to activate the receptor at the glycine, co-agonist binding site. Glutamate site agonists selected were L-glutamate and NMDA. Selected glycine site co-agonists were glycine, D-cycloserine, and aminocyclopropane-carboxylic acid (ACPC). In each case, the agonist was selected because it was the natural agonist (glutamate or glycine) or was among the most highly characterized of the many synthesized agonists available.
Statistical analysis
All data were entered into an electronic database using Excel 6.0 (Microsoft) and Prism 2.0 (GraphPad, Inc.) and were normalized to the number of defects per 1000 embryos. Means were compared with a single-factor analysis of variance, followed by Fisher post hoc analysis (Statview 2.0, Abacus Concepts, Inc.), or with a Student's t test developed for comparison of groups with differing n (29):
RESULTS
ACPC and NMDA were ineffective, affording no detectable protection at any of the concentrations tested here. D-Cycloserine and glutamate each showed some protective effect at a dose of 50 nmol/ day (Fig. 3) , but the most protective effect was provided by glycine at 50 nmol/day (Fig. 3) . Glycine was also the only NMDA receptor agonist that gave a statistically significant protective effect at more than one concentration (Fig. 3) . For each agonist that afforded protection against homocysteine-induced developmental abnormalities, the effect was highly dose dependent (Fig. 4) .
After treatment with homocysteine at 5 mol/day in the absence of any NMDA receptor agonist, the percentage of total defects that fell into each category was as follows: orofacial defects including obvious branchial arch abnormalities, 5.8%; torsion defects, 6.4%; cranial closure defects resembling exencephaly, 16.1%; spinal closure defects resembling spina bifida, 34.8%; and multiple defects, 36.7%. About half of the embryos in the multiple defects category had a cranial closure defect as one component. For each experiment, the total number of defects varied less widely than the number of defects within a given category. For example, if the number of cranial defects for a given experiment was lower than average, or perhaps even zero, it was likely that the number of spinal or multiple defects would be higher than average. It was not possible to predict with accuracy the proportion of embryos that would manifest a particular kind of defect. Possible sources of this variation could include differing origins of the eggs, seasonal variation in the robustness of the embryos, differences in the treatment techniques among different members of the research team, treatment at different times of the day, or differences in the state of maturity of the embryos at the time of treatment. None of these can be excluded with certainty as a contributor to the variability in defects, and the variability could be the result of the combined effects of all of them. Nevertheless, each of these conditions was controlled as much as possible, as described below.
Pathogen-free chicken embryos from SPAFAS were supplied with flock numbers; because of the duration of this study and the large number of embryos that were used, embryos were derived from different flocks. There were slight but statistically insignificant differences among the flocks in the survival rate as well as the overall rate of occurrence Figure 3 . The total number of developmental abnormalities that followed treatment of avian embryos with L-homocysteine thiolactone (5 mol/day) is compared with the number that occur after treatment with vehicle only or with Lhomocysteine thiolactone (Hcys) and NMDA receptor agonists. For each agonist except glycine, the dose represented here is that which resulted in the lowest number of developmental abnormalities when it was given with L-homocysteine thiolactone:N-methyl-D-aspartate (NMDA), 50 nmol/day; aminocyclopropane-carboxylic acid (ACPC), 5 nmol/day, Dcycloserine (DCS), 50 nmol/day; and glutamic acid (GLU), 50 nmol/day. Glycine at doses of 500 nmol/day (GLY Ϫ1 ) and 50 nmol glycine/day (GLY Ϫ3 ) had a significant protective effect. Bars ϭ sem. of defects; however, embryos from all flocks showed similar variation among defects per experiment. Likewise, there was an annual cycle of variation in embryo survival, with a midsummer acme and a midwinter nadir. This cycle affected treated and control embryos equally, and had no measurable effect on the rate of defects among survivors or variation among defects per experiment.
Regarding differences in the timing or technique of treatment, embryo incubations were always begun at exactly the same time of day, and the 4 h/28 h/52 h treatments were delivered with precision. During the 2 years these experiments were conducted, almost all treatments were performed by only two persons, and no persistent differences of any kind were detectable between their respective results.
We can confirm that the state of maturity of the embryo at the time of homocysteine treatment may have an effect on the kind of defect that results. For example, embryos that are treated only once prior to the onset of neurulation show only cranial closure defects (30), whereas embryos treated only late in the process of neurulation show spinal defects as well (9) . Variations in embryo maturity at the time of treatment could have resulted from small temperature variations that could not be controlled precisely, for example, during delivery and storage.
In summary, the kinds of defects that occurred per experiment were more variable than the absolute number of defects, but the origin of this variability could only be estimated. Likewise, the reduction in developmental abnormalities that resulted from the use of NMDA receptor agonists was not specific to any category: there was no statistically provable relationship between any of the agonists and a change within any specific category of defect.
NMDA receptor agonists, including those used in this study, generally are considered to be dangerous because they may induce epileptiform seizures as well as apoptosis of fully differentiated neurons (see Discussion below). Nevertheless, the agonists used in this study were generally benign; only NMDA produced a statistically significant increase in abnormal embryos when it was given at the rate of 500 nmol/ day. In this case, 9.23 Ϯ 3.4% of the surviving embryos showed developmental abnormalities vs. 1.6 Ϯ 0.2% of the embryos that received vehicle only, but even this increase is small compared with that resulting from 5 mol/day of homocysteine, after which 38.59% of surviving embryos had abnormalities (see Fig. 3 ). Note that the same dose of NMDA given simultaneously with 5 mol/day of homocysteine had neither a positive nor a negative effect: 38.59% of surviving embryos had neural tube or neural crest abnormalities after treatment with homocysteine vs. 38.71% of surviving embryos with neural tube or neural crest abnormalities after treatment with homocysteine and NMDA.
Whereas glycine acted to restore normal development among the survivors of homocysteine treatment, neither glycine nor any of the other NMDA receptor agonists had any effect on survival among the treated embryos whether given alone or with a teratogenic dose of homocysteine (Fig. 5) .
DISCUSSION
These results support the hypothesis that homocysteine may induce abnormal development by acting as an antagonist of the NMDA receptor or a related receptor, since administration of NMDA receptor agonists coincident with a teratogenic dose of homocysteine resulted in a decrease in the occurrence of developmental abnormalities. This protective effect was most notable for glycine. The good performance of glycine in this context might have been predicted based on the work of Lipton et al. (12) , who showed that homocysteine acts as a competitive antagonist at the NMDA receptor glycine co-agonist site, but as an agonist for the glutamate recognition site. In this way glycine would be expected to compete with, and thus reverse the inhibitory action of, homocysteine and possibly also unmask the ability of homocysteine to act as an agonist.
In studies of the fully developed central nervous system, NMDA receptor agonists can be toxic whereas NMDA receptor antagonists are protective against these toxic effects (31). However, in the Figure 4 . The ability of the NMDA receptor agonists to provide protection against homocysteine-induced developmental defects was dose dependent. In this graph, the effects of D-cycloserine (DCS) and glutamic acid (GLU) are shown for doses of 5, 50, and 500 nmol/day. The effects of doses of glycine (GLY) are shown for 5, 50, 500, and 5000 nmol/day. The ordinate axis is a derived scale called 'Protection Index' representing the difference between the number of defects/ 1000 survivors expected with 5 mol/day L-homocysteine thiolactone alone (see Fig. 3 ) and the number that actually occurred when L-homocysteine thiolactone and an agonist were given simultaneously; thus, each embryo represented on the ordinate is one that was normal, and a larger number represents a greater ability to protect against homocysteineinduced abnormalities. Bars representing sem are omitted for clarity, but can be seen for the most protective doses in Fig. 3. context of neural tube development, NMDA receptor antagonists appear to be toxic whereas agonists appear to be protective. During neural tube closure and neural crest migration, the greater danger appears to be presented by NMDA receptor antagonists; agonists generally did not induce significant defects by themselves in the present study, but gave a protective effect when delivered with homocysteine. NMDA receptor antagonists may also disrupt normal brain development during early postnatal life in the rat (32), but a protective role for agonists has not been shown in that model.
The results of the present study indicate that an NMDA receptor or NMDA-like receptor may regulate some key process in neural tube closure and neural crest migration, but they do not show what that process may be. However, it is biologically plausible that this unknown key process could in fact be apoptosis or programmed cell death. Programmed cell death is an essential, beneficial feature of early development of the neural tube and the neural crest (33) (34) (35) that is regulated by the NMDA receptor in later stages of development, as described above. A decrease in beneficial cell death results in neural tube closure defects, for example, those that have been described in p53 loss-of-function mutations in mice (36) . Thus, it may be hypothesized that antagonists of the NMDA receptor such as MK801 and dextromethorphan (26) or, in the present case, homocysteine, may be teratogenic because they interfere with an essential program for beneficial cell death. The phenotype resulting from this decrease in beneficial cell death should include an abundance of cells in the effected areas rather than the obvious deficits in the effected areas that follow increased apoptosis in the neural tube (e.g., related to retinoic acid-induced neural tube defects) (37) . Indeed, the exposed brains of exencephalic mice in the p53 knockout model (36) resemble those of hyperhomocysteinemic chicken embryos (see ref 9 , Fig. 6 ).
NMDA receptor antagonists, like the agonists, may induce programmed cell death in some developing neurons (32) ; thus, an equilibrium between the yin and yang of agonist vs. antagonist may be a key to normal development of the neural tube and neural crest, beginning at a very early stage (as indicated by the present investigation) and continuing into later stages, as shown in the developing rat central nervous system (32) .
The pharmacologic evidence given here implies the involvement of a receptor that interacts with homocysteine and other NMDA receptor antagonists, but the nature of this putative receptor is not yet known. There are many possibilities. Functional NMDA receptors are present in the early chicken embryo (38) and there is evidence from Western blots that the NR1 subunit protein is already present by stage 10, during the first 34 h of development (M. Thomas, personal communication). The NMDA receptor is a heterooligomer composed of NR1 (a-h) , NR2 (A-D) , and NR3 subunits (39 -42) ; thus, there is the potential for multiple combinations in the receptor complex. Alternatively, there is the possibility that the NMDA agonist/antagonist effects reported here may be mediated by an NMDA-like receptor that has not been described. Investigations into these possibilities have been undertaken in this and other laboratories.
Hyperhomocysteinemia is associated with increased embryo death, as shown here and in an earlier study (9) , and is associated with spontaneous abortion and fetal death in human populations (43, 44) . As is the case for the association between hyperhomocysteinemia and neural tube defects, there is no agreement regarding a mechanism for this increase in embryo and fetal death. The results of the present study imply that at least in the case of the avian embryo model, the mechanism for induction of neural tube defects is different from the mechanism for embryo death, since the survival rate of the embryos was unaffected when the rate of developmental abnormalities among the survivors Figure 5 . NMDA receptor agonists had no effect on the survival of treated embryos. The survival rate hovered around 90% whether the set of embryos was treated with vehicle alone or with 50 nmol/day glutamic acid (GLU), 5 nmol/day glycine (GLY), 5 nmol/day animocyclopropane-carboxylic acid (ACPC), 50 nmol/day D-clycoserine (DCS), or 50 nmol/ day N-methyl-D-aspartic acid (NMDA). When the same doses of NMDA receptor agonists were given with 5 mol/day L-homocysteine thiolactone (Hcys), the survival rates were no different from that which obtained with Hcys alone, i.e., ϳ40%.
was decreased significantly. It is possible that homocysteine may exert a lethal effect by acting on the embryonic vasculature. There appear to be fewer extraembryonic vessels after treatment of chicken embryos with homocysteine, and the branching patterns are less complex (unpublished observations of the authors, supported by observations by K. Eastep, personal communication). In humans, the approximate equivalent is the growth of the placental vasculature, which is also affected adversely by hyperhomocysteinemia (43, 44) . Embryonic blood vessels expand by endothelial outgrowth (45); consequently, their failure to grow and the failure of the vasculature to arborize fully would result from inhibition of endothelial growth. Since homocysteine has a negative effect on the growth of endothelia in vivo (46) and in vitro (47), we may hypothesize one mechanism to explain the lethal effect of hyperhomocysteinemia: inhibition of growth of the extraembryonic vasculature may starve the embryo.
Inhibition of intraembryonic angiogenesis by the same mechanism also could result in abnormal development of organs with an insufficient blood supply. Indeed, disruption of vascular development can cause major developmental defects. It has been shown that hemifacial microsomia and microphthalmia may result from failed vascular development in humans (48) . This result is of special interest to the present study, given the abnormalities of the eye and branchial arches described above. It is less likely that failed angiogenesis is a contributor to the neural tube closure defects described here since the vasculature is insufficiently developed to permit the blood to circulate effectively between the embryo and the area vasculosa before stage 18, but neural tube closure is essentially complete at stage 18 in the chicken embryo (49; ref 50, p. 604) .
Studies of the effects of homocysteine on cells in vitro have been criticized when they have used reduced homocysteine, homocystine, or homocysteine thiolactone as these forms are extremely scarce in vivo, where the vast majority of serum homocysteine is bound to albumin (51). Although we have used L-homocysteine or L-homocysteine thiolactone for the present and earlier studies (9, 26) , the same criticism should not apply here: unlike the case where homocysteine or its thiolactone is added to culture medium in vitro and therefore may reach cultured cells unbound, it is unlikely that homocysteine given to embryos in ovo could reach the embryos without becoming bound to albumin. Homocysteine, applied to the membranes surrounding the embryo, may pass either through the albumin-rich milieu that contains the early embryo or may at later stages enter the albumin-rich embryonic serum via the extraembryonic vasculature (9) .
Various forms of homocysteine as well as homocystine (52) have been shown to have growth or other cellular effects in vitro, and we do not know which or how many forms of homocysteine may contribute to the teratogenic effects reported here and in earlier studies of embryos in vivo (9, 26) . However, there is a rapid exchange among the various forms of homocysteine in vivo, and when the amount of albuminbound homocysteine increases, the other forms may increase consequently (53) . The data in this study support the hypothesis that homocysteine may induce abnormal development among neural tube and neural crest derivatives by acting as an antagonist of the NMDA receptor. However, about half of the homocysteine-induced abnormalities remained after application of the best protective agent in this study, glycine. This result could mean that some mechanism other than inhibition of an NMDA receptor is responsible for this residual damage or that the pharmacologic conditions needed for higher levels of protection have not yet been found. Indeed, the putative NMDA-like receptor that apparently is responsible for the protective effect appears to differ pharmacologically from previously described NMDA receptors; for example, the protective effects were not mimicked by the high efficacy partial agonist aminocyclopropanecarboxylic acid.
The fact that a large proportion of the homocysteine-induced abnormalities appear to be due to its NMDA receptor antagonism presents another possibility that needs to be explored experimentally. Homocysteine may have the potential to interact with other teratogenic NMDA receptor antagonists, additively or synergistically, to promote abnormal development (54) .
